Download Our DHN Survey Result 2024
Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Johnson & Johnson to Acquire Shockwave Medical for $13.1 Bn

Written by : Jayati Dubey

April 8, 2024

Category Img

With this acquisition, Johnson & Johnson aims to bolster its position in cardiovascular intervention, one of the fastest-growing global medtech markets.

In a recent development, Johnson & Johnson has announced plans to acquire US-based Shockwave Medical for $13.2 billion.

Reportedly, Johnson & Johnson has entered into a definitive agreement with Shockwave to acquire all outstanding shares of the latter for $335.00 per share in cash, amounting to an enterprise value of approximately $13.1 billion, including cash acquired.

This transaction, approved by both companies' boards of directors, marks a strategic endeavor for Johnson & Johnson to expand its presence in cardiovascular intervention and tap into higher-growth markets.

The acquisition of Shockwave aligns with Johnson & Johnson's strategic focus on innovative medicine and medtech, particularly in addressing cardiovascular disease, which remains the leading cause of death globally.

With this acquisition, Johnson & Johnson aims to bolster its position in cardiovascular intervention, which is one of the fastest-growing global medtech markets with substantial unmet patient needs.

Impact on Cardiovascular Treatment

The addition of Shockwave in Johnson & Johnson's medtech portfolio extends its reach into two high-growth segments of cardiovascular intervention including coronary artery disease (CAD) and peripheral artery disease (PAD).

Shockwave is renowned for its innovative intravascular lithotripsy (IVL) technology, which offers a minimally invasive treatment for calcified arterial lesions in both CAD and PAD cases.

This technology, combined with Johnson & Johnson's existing expertise, is expected to enhance patient outcomes and treatment options in cardiovascular care significantly.

This acquisition follows Johnson & Johnson medtech's successful acquisitions of Abiomed and Laminar, reinforcing its commitment to advancing healthcare solutions.

By integrating Shockwave's IVL technology, Johnson & Johnson aims to solidify its position as a category leader in four high-growth cardiovascular segments.

Shockwave's IVL technology utilizes sonic pressure waves to crack calcium lesions in arterial walls, thereby restoring blood flow and alleviating symptoms such as pain or heart attack.

With claims of treating approximately 400,000 patients globally, Shockwave has established itself as a pioneer in intravascular lithotripsy, providing innovative solutions for complex cardiovascular conditions.

Shockwave's pipeline includes advancements in CAD and PAD treatment, as well as potential applications in new indications such as carotid artery disease and structural heart disease.

Additionally, Shockwave's recent acquisition of Neovasc and its reducer system for refractory angina further expands its product portfolio and market presence.

Operational & Financial Implications

The transaction is expected to be operationally accretive upon closing, although it is projected to have a slightly dilutive effect on adjusted earnings per share in 2024 and 2025.

Further, Johnson & Johnson plans to fund the acquisition through a combination of cash on hand and debt while maintaining a solid balance sheet to support its capital allocation priorities.

Following the completion of the transaction, Shockwave will operate as a business unit within Johnson & Johnson Medtech. Michael Bodner, global head, Heart Recovery at Johnson & Johnson, will assume responsibility for the Shockwave business unit.

Isaac Zacharias, Shockwave's president and chief commercial officer, will transition to become Worldwide president of Shockwave, reporting to Michael Bodner. Shockwave's president and CEO, Doug Godshall, will provide advisory support through the transition phase.

The closing of the transaction is anticipated to occur by mid-year 2024, subject to shareholder and regulatory approvals. Upon completion, Shockwave's common stock will no longer be listed for trading on the Nasdaq Global Select Market.

JP Morgan Securities LLC is serving as financial advisor to Johnson & Johnson, while Freshfields Bruckhaus Deringer LLP is providing legal counsel. Perella Weinberg partners is acting as financial advisor to Shockwave, with legal advisory services from Fenwick & West LLP.

About Chime India

The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving senior digital health leaders. CHIME includes more than 5,000 members in 56 countries and two US territories and partners with over 150 healthcare IT businesses and professional services firms. CHIME enables its members and business partners to collaborate, exchange ideas, develop professionally and advocate the effective use of information management to improve the health and care throughout the communities they serve. CHIME's members are chief information officers (CIOs), chief medical information officers (CMIOs), chief nursing information officers (CNIOs), chief innovation officers (CIOs), chief digital officers (CDOs), and other senior healthcare leaders. The CHIME India Chapter became the first international chapter outside North America in 2016 and is now a community of over 70+ members in India. For more information, please visit


Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.


© Digital Health News 2024